MedTrace Logo

Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window

NCT01770197 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2014-12-10

No results posted yet for this study

Summary

The time window for intravenous recombinant tissue plasminogen activator treatment in ischemic stroke patients has been extended to 4.5h. Little is known about intravenous recombinant tissue plasminogen activator use in the 3-4.5 hour time window among Chinese stroke patients. This exploratory study was to describe the feasibility and outcome of treatment with intravenous recombinant tissue plasminogen activator in the expanded time window, and to offer suggestions for future clinical work in China.

Conditions

Interventions

DRUG

IV rt-PA

IV rt-PA treatment

Sponsors & Collaborators

  • Wuhan General Hospital of Guangzhou Military Command

    lead OTHER

Principal Investigators

  • Wuhan G H, High · Wuhan General Hospital of Guangzhou Command

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2014-12-31
Completion
2014-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01770197 on ClinicalTrials.gov